QUOTED. Jan. 16, 2018. Kelly Londy.
Executive Summary
Check out what Lumicell CEO Kelly Londy had to say about why the device-maker is developing its LUM system to treat prostate, colorectal, esophageal and pancreatic cancers.
"We think [the LUM system] will have wide ability to detect a variety of cancers because of the activation mode of [the firm's LUM015 cathepsin-activatable fluorescent optical contrast agent]. Unlike chemotherapy, which attacks all the cells, ours is different in that it's a protease, so the cancer cells reach out and grab it and pull it in, and when it does that the molecule cleaves and fluoresces. So only the cells around the tumor glow, not all the cells." –Kelly Londy, CEO, Lumicell
> Find out more: San Antonio Breast Cancer Symposium: New Diagnostics From Myriad, Lumicell, Agendia
Click here for a free trial of Medtech Insight